Dean Faculty of Science and Technology
In 1996 Mikael Elofsson obtained his Ph.D. in organic chemistry at the Lund Institute of Technology, Lund, Sweden. In the group of Professor Jan Kihlberg he worked with synthesis of glycosylated amino acids and solid-phase glycopeptide synthesis. Thereafter he spent three years as postdoc in the lab of Professor Craig M. Crews at Yale University, CT, USA working primarily on epoxyketone proteasome inhibitors. The work eventually led to the drug Kyprolis (Carfilzomib) that was approved by the US Food and Drug Administration in 2012 and by the European Medicines Agency in 2015.
In 1999 he was recruited to Umeå University and in 2008 he was appointed Professor. Since 2017 he is the Dean of the Faculty of Science and Technology. His lab focuses on chemical approaches to investigate how bacteria and viruses cause infection and identification of antibacterial and antiviral compounds, for example natural products, glycoconjugates and small molecules. Starting points are typically generated by screening-based technologies followed by iterative design, synthesis and evaluation in biochemical, biophysical systems and infection models in vitro and in vivo.
Mikael Elofsson on Linkedin
Mikael Elofsson on Google Scholar
